This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826.
FACT-JACIE Cellular Therapy Accreditation Manual 4th edn, October 2008, available at http://www.jacie.org/collage/images/potter/tempFiles/potterTmpFile_uuid_54633/FACT-JACIE%2B4th%2Bed%2BStandards.pdf.
Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A et al. Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008; 42: 9–14.
Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385–390.
Akizawa T, Shishido K, Koshikawa S . The effects and pharmacokinetics of rhG-CSF in patients with chronic renal failure. Artif Organs 1995; 19: 1251–1257.
Product monograph for Neupogen, Amgen Canada Inc. Last revised 18 August 2009. Accessed via http://www.amgen.ca/Neupogen.pdf.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ahmad, I., Kiss, T., Lachance, S. et al. Allogeneic hematopoietic stem cell collection from a donor with end-stage renal disease. Bone Marrow Transplant 47, 157–158 (2012). https://doi.org/10.1038/bmt.2011.31
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.31